过去一年中添加的文章，按日期排序
Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis
S Zhou, N Kishi, P Alerasool, NC Rohs - Targeted Oncology, 2024 - Springer
20 天前 - … The risk of high-grade rash was significantly increased in patients treated with
erlotinib or gefitinib (Table 3 of the ESM; Fig. 3A). In subgroup analyses based on the control arm, …
erlotinib or gefitinib (Table 3 of the ESM; Fig. 3A). In subgroup analyses based on the control arm, …
[引用][C] CO161 Adherence and Persistence To Oral Targeted Therapies for Non-Small-Cell Lung Cancer and Association With Survival Outcomes
S Nduaguba, A Cipoletti, R Misra - Value in Health, 2024 - valueinhealthjournal.com
21 天前 - … , Brigatinib, or Crizotinib) or EGFR inhibitor (EGFRi: Afatinib, Erlotinib, or Gefitinib).
Patients were followed from treatment commencement until death, loss to follow-up, or end of …
Patients were followed from treatment commencement until death, loss to follow-up, or end of …
Revolutionizing non‐melanoma skin cancer treatment: Receptor tyrosine kinase inhibitors take the stage
24 天前 - … on the treatment potential of several RTKIs, namely cetuximab, erlotinib, gefitinib, …
these targeted therapies hold great promise for the treatment of NMSCs. However, it is …
these targeted therapies hold great promise for the treatment of NMSCs. However, it is …
Evaluating generalizability of landmark randomized controlled trials in common metastatic cancers using machine learning-based emulated trials.
24 天前 - … We used inverse probability of treatment weighted survival … (osimertinib) vs control
(gefitinib or erlotinib) was 18.9 mos … individual patient-level estimation of real-world treatment …
(gefitinib or erlotinib) was 18.9 mos … individual patient-level estimation of real-world treatment …
The association between osimertinib and nutritional deficiency among patients with non-small cell lung cancer.
24 天前 - … patients with NSCLC who received either osimertinib or other EGFR-TKIs (afatinib,
dacomitinib, erlotinib, gefitinib). The … 4264 patients who received osimertinib to patients who …
dacomitinib, erlotinib, gefitinib). The … 4264 patients who received osimertinib to patients who …
Dermatologic adverse events in EGFR-TKIs: A real-world analysis.
E Paton, RJ Friedman, JP Cetnar - Journal of Clinical Oncology, 2024 - ascopubs.org
24 天前 - … DAEs affecting NSCLC patients treated with EGFR … patients about side effects and
giving patients a more nuanced understanding of what to expect before undergoing treatment…
giving patients a more nuanced understanding of what to expect before undergoing treatment…
Associations of early adverse events with clinical outcomes in patients with NSCLC treated with EGFR tyrosine kinase inhibitors.
FJ Lin, WY Lin, CC Wang, JY Shih - 2024 - ascopubs.org
24 天前 - … included 1,605 patients on gefitinib, 848 on erlotinib, and 1,236 … treatment was
highest for afatinib, particularly with diarrhea (76.7%) and stomatitis (14.9%), followed by erlotinib …
highest for afatinib, particularly with diarrhea (76.7%) and stomatitis (14.9%), followed by erlotinib …
Cutaneous adverse event profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer: A meta-analysis of phase 3 …
S Zhou, P Alerasool, N Kishi, NC Rohs - 2024 - ascopubs.org
24 天前 - … Results: 35 RCTs comprising 16,151 patients were included. In addition to all- and
high-… increased in patients treated with erlotinib or gefitinib but not in those treated with other …
high-… increased in patients treated with erlotinib or gefitinib but not in those treated with other …
[HTML][HTML] Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non …
37 天前 - … (2L), 3L, and ≥4L therapy, respectively. In patients who received osimertinib as 2L
therapy, the median PFS values in response to prior afatinib, erlotinib and gefitinib treatment …
therapy, the median PFS values in response to prior afatinib, erlotinib and gefitinib treatment …
Reduced Risk of Incident Chronic Obstructive Pulmonary Disease Following EGFR-targeted Therapies in Patients With Lung Cancer
SYE Chan, PC Huang, KSK Ma - C46. CLINICAL AND …, 2024 - atsjournals.org
52 天前 - … COPD risk in lung cancer patients treated with different EGFR inhibitor (… - gefitinib,
erlotinib, afatinib, and osimertinib - for lung cancer and the risk of developing COPD. Patients …
erlotinib, afatinib, and osimertinib - for lung cancer and the risk of developing COPD. Patients …